Bracco has invested in Chinese facilities to produce and ship contrast media. The investments are being made through a joint venture with Shanghai-based Sine Pharmaceutical. The Bracco-Sine production plant opened in June in Shanghai's high-tech district. It will focus on the final cycle in contrast media production. Chinese workers will formulate drug solutions from basic ingredients sent from Italy, then prepare, seal, and sterilize individual doses.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Key MRI Findings Predictive of Treatment Response for Unresectable Hepatocellular Carcinoma
July 14th 2025For patients with unresectable hepatocellular carcinoma, a pre-treatment MRI finding of LI-RADS tumor in vein was associated with over an 86 percent lower likelihood of responding to transcatheter arterial chemoembolization (TACE) and targeted immunotherapy.